Analysts expect Adamis Pharmaceuticals Corp (NASDAQ:ADMP) to post ($0.11) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Adamis Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.13) and the highest estimate coming in at ($0.10). Adamis Pharmaceuticals posted earnings of ($0.29) per share during the same quarter last year, which suggests a positive year over year growth rate of 62.1%. The business is scheduled to report its next earnings results on Friday, August 9th.
According to Zacks, analysts expect that Adamis Pharmaceuticals will report full year earnings of ($0.44) per share for the current year, with EPS estimates ranging from ($0.57) to ($0.35). For the next financial year, analysts anticipate that the business will report earnings of ($0.06) per share, with EPS estimates ranging from ($0.30) to $0.19. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Adamis Pharmaceuticals.
Adamis Pharmaceuticals (NASDAQ:ADMP) last released its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.15) by ($0.04). Adamis Pharmaceuticals had a negative net margin of 239.53% and a negative return on equity of 94.94%. The firm had revenue of $4.91 million for the quarter, compared to the consensus estimate of $5.95 million.
A number of research analysts have issued reports on ADMP shares. Zacks Investment Research upgraded Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Tuesday, July 16th. B. Riley cut Kindred Biosciences from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $18.00 to $8.50 in a research note on Tuesday, July 16th. Raymond James reiterated a “buy” rating on shares of Canadian Natural Resources in a research note on Friday, May 10th. Finally, Dawson James started coverage on Adamis Pharmaceuticals in a research note on Tuesday, July 2nd. They set a “buy” rating for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $4.72.
Shares of NASDAQ ADMP traded down $0.10 during mid-day trading on Tuesday, hitting $1.17. 512,412 shares of the stock traded hands, compared to its average volume of 507,552. The company has a quick ratio of 1.24, a current ratio of 1.53 and a debt-to-equity ratio of 0.03. Adamis Pharmaceuticals has a 52 week low of $1.17 and a 52 week high of $4.25. The stock has a fifty day moving average of $1.35.
Large investors have recently made changes to their positions in the business. DekaBank Deutsche Girozentrale purchased a new position in shares of Adamis Pharmaceuticals during the 1st quarter valued at about $3,360,000. National Asset Management Inc. raised its stake in shares of Adamis Pharmaceuticals by 28.9% during the 1st quarter. National Asset Management Inc. now owns 29,920 shares of the specialty pharmaceutical company’s stock valued at $64,000 after buying an additional 6,710 shares during the last quarter. Leisure Capital Management raised its stake in shares of Adamis Pharmaceuticals by 4.5% during the 1st quarter. Leisure Capital Management now owns 115,724 shares of the specialty pharmaceutical company’s stock valued at $244,000 after buying an additional 4,967 shares during the last quarter. Wedbush Securities Inc. purchased a new position in shares of Adamis Pharmaceuticals during the 1st quarter valued at about $39,000. Finally, Virtu Financial LLC purchased a new position in shares of Adamis Pharmaceuticals during the 1st quarter valued at about $43,000. Institutional investors and hedge funds own 21.99% of the company’s stock.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Featured Story: Limitations to arbitrage trading
Get a free copy of the Zacks research report on Adamis Pharmaceuticals (ADMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.